These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28978569)

  • 1. Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.
    Zerra PE; Cox C; Baldwin WH; Patel SR; Arthur CM; Lollar P; Meeks SL; Stowell SR
    Blood; 2017 Dec; 130(23):2559-2568. PubMed ID: 28978569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
    Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
    Front Immunol; 2020; 11():1293. PubMed ID: 32670285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A.
    Navarrete A; Dasgupta S; Delignat S; Caligiuri G; Christophe OD; Bayry J; Nicoletti A; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2009 Nov; 7(11):1816-23. PubMed ID: 19682235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice.
    Lai JD; Cartier D; Hartholt RB; Swystun LL; van Velzen AS; den Haan JMM; Hough C; Voorberg J; Lillicrap D
    J Thromb Haemost; 2018 Mar; 16(3):533-545. PubMed ID: 29285874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.
    Zhang AH; Skupsky J; Scott DW
    Blood; 2011 Feb; 117(7):2223-6. PubMed ID: 21160036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation.
    Zerra PE; Arthur CM; Chonat S; Maier CL; Mener A; Shin S; Allen JWL; Baldwin WH; Cox C; Verkerke H; Jajosky RP; Tormey CA; Meeks SL; Stowell SR
    Front Immunol; 2020; 11():905. PubMed ID: 32582142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.
    Jing W; Chen J; Cai Y; Chen Y; Schroeder JA; Johnson BD; Cui W; Shi Q
    Blood Adv; 2019 Oct; 3(20):3099-3110. PubMed ID: 31648333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
    Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia].
    Ishiguro A
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(6):476-84. PubMed ID: 22214808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
    Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
    J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors - cellular aspects and novel approaches for tolerance.
    Scott DW
    Haemophilia; 2014 May; 20 Suppl 4(0 4):80-6. PubMed ID: 24762281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro.
    Werwitzke S; Vollack N; von Hornung M; Kalippke K; Kutzschbach J; Trummer A; Ganser A; Tiede A
    Thromb Haemost; 2015 Nov; 114(6):1127-35. PubMed ID: 26245154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII alloantibodies in hemophilia.
    Jacquemin MG; Saint-Remy JM
    Curr Opin Hematol; 2004 May; 11(3):146-50. PubMed ID: 15257012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion.
    Patel SR; Gibb DR; Girard-Pierce K; Zhou X; Rodrigues LC; Arthur CM; Bennett AL; Jajosky RP; Fuller M; Maier CL; Zerra PE; Chonat S; Smith NH; Tormey CA; Hendrickson JE; Stowell SR
    Front Immunol; 2018; 9():2516. PubMed ID: 30505302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
    Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
    Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of immune tolerance induction in hemophilia A.
    Schep SJ; Schutgens REG; Fischer K; Boes ML
    Blood Rev; 2018 Jul; 32(4):326-338. PubMed ID: 29482894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.